JASON EHRLICH - 20 Jan 2022 Form 4 Insider Report for Kodiak Sciences Inc. (KOD)

Role
Chief Medical Officer and Chief Development Officer
Signature
/s/ David Peinsipp, Attorney-in-Fact for Jason Ehrlich
Issuer symbol
KOD
Transactions as of
20 Jan 2022
Net transactions value
-$375,978
Form type
4
Filing time
24 Jan 2022, 16:17:54 UTC
Previous filing
22 Dec 2021
Next filing
18 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KOD Common Stock Options Exercise $71,516 +6,950 +13% $10.29 58,491 20 Jan 2022 Direct
transaction KOD Common Stock Sale $50,680 -808 -1.4% $62.72* 57,683 20 Jan 2022 Direct F1, F2
transaction KOD Common Stock Sale $153,547 -2,416 -4.2% $63.55* 55,267 20 Jan 2022 Direct F1, F3
transaction KOD Common Stock Sale $194,689 -2,995 -5.4% $65.00* 52,272 20 Jan 2022 Direct F1, F4
transaction KOD Common Stock Sale $35,329 -533 -1% $66.28* 51,739 20 Jan 2022 Direct F1, F5
transaction KOD Common Stock Sale $13,249 -198 -0.38% $66.91* 51,541 20 Jan 2022 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KOD Stock Option (Right to Buy) Options Exercise $0 -6,950 -3.1% $0.000000 218,538 20 Jan 2022 Common Stock 6,950 $10.29 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $62.02 to $62.98, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in these footnotes.
F3 The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $63.135 to $64.11, inclusive.
F4 The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $64.395 to $65.33, inclusive.
F5 The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $65.85 to $66.41, inclusive.
F6 The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $66.91 to $66.99, inclusive.
F7 Twenty-five percent of the shares subject to the option vested on September 1, 2019, and 1/48th of the shares subject to the option vest on the same day of each month thereafter.

Remarks:

Chief Medical Officer and Chief Development Officer